Headlands Technologies’s Pacific Biosciences PACB Stock Holding History

Headlands Technologies’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$21.1K	Buy	+12,537	New	+$18.2K	﹤0.01%	692
2026 Q1	–	Sell	-733,840	Closed	-$1.37M	–	908
2025 Q4	$1.37M	Buy	+733,840	New	+$1.41M	0.11%	215
2025 Q2	–	Sell	-240	Closed	-$283	–	1436
2025 Q1	$283	Buy	+240	New	+$368	﹤0.01%	1079
2024 Q2	–	Sell	-8,555	Closed	-$32.1K	–	1491
2024 Q1	$32.1K	Buy	+8,555	New	+$50.1K	0.01%	812

Other funds holding PACB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Headlands Technologies's PACB Position: Q2 2026 in Review

Headlands Technologies opened a new position in Pacific Biosciences (PACB) in Q2 2026: 12,537 shares worth $21.1K. The stake represents ﹤0.01% of the portfolio and ranks #692 among its holdings. This is a return to the name: Headlands Technologies previously reported a position in PACB as recently as Q4 2025.

Headlands Technologies first reported a position in PACB in Q1 2024 and has held it in 4 quarters since. The position peaked at $1.37M in Q4 2025. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

Headlands Technologies held 12,537 shares of Pacific Biosciences worth $21.1K as of Q2 2026.
Pacific Biosciences was a new Headlands Technologies position in Q2 2026.
Pacific Biosciences made up ﹤0.01% of Headlands Technologies's portfolio in Q2 2026, its #692 holding.
Headlands Technologies first reported a position in Pacific Biosciences in Q1 2024 and has held it in 4 quarters since.
Headlands Technologies's Pacific Biosciences position peaked at $1.37M in Q4 2025.
223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Headlands Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.